摘要
急性淋巴细胞白血病(Acute lymphoblastic leukemia,ALL)是一种血液性的恶性肿瘤,在成人急性白血病中较为常见。白血病细胞的生物学特征是涉及前体淋巴细胞增殖分化相关的染色体异常和基因改变。尽管联合化疗方法已取得重大进展,但耐药性及复发性仍为治疗的难题,因此就ALL基因方面的机制通路,及靶向治疗药物进行综述,旨在为临床新药研发提供参考。
Acute lymphoblastic leukemia is a hematological malignant tumor, which is more common in adult acute leukemia. The biological characteristics of leukemic cells are chromosomal abnormalities and genetic alterations related to the proliferation and differentiation of precursor lymphocytes. Although significant progress has been made in combination chemotherapy, medicine resistance and relapse are still difficult problems in treatment. Therefore, the mechanism of ALL gene mutation, pathway and targeted therapy are reviewed in this paper, in order to provide reference for clinical new drug research and development.
作者
刘佳
江振洲
张陆勇
LIU Jia;JIANG Zhenzhou;ZHANG Luyong(Jiangsu Key Laboratory of Drug Screening,China Pharmaceutical University,Nanjing 210009,China;Center for Drug Research and Development,Guangdong Pharmaceutical University,Guangzhou 510006,China)
出处
《药物评价研究》
CAS
2019年第10期2100-2105,共6页
Drug Evaluation Research
